The board of directors of Parmax Pharma Limited has its meeting held today inter alia considered and approved the Audited financial statements of the company for the quarter and year ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma's revenue from operations surged to ₹28.20 crore in FY25 from ₹11.05 crore in FY24 — a growth of about 155%. Despite this strong top-line jump, the company remained in the red with a net loss of ₹2.09 crore, although this was a big improvement from the ₹5.75 crore loss in FY24. Q4 FY25 alone saw a loss of ₹1.49 crore on revenue of ₹4.83 crore. An exceptional item of ₹1.07 crore, linked to a December 2023 factory fire, hit the books. The balance sheet shows negative shareholders' equity of ₹(1.99) crore, meaning liabilities exceed assets, and the auditor flagged qualifications on how fire-related damages (₹3.69 crore parked under current assets) and a ₹40 lakh mutual fund investment held in the Managing Director's name (alleged violation of Section 187 of the Companies Act) were accounted for.
The stock may face pressure given the negative net worth, continued losses, and auditor qualifications, but revenue growth and sharply reduced losses are positives. The going concern uncertainty raised by auditors adds risk for existing shareholders.